The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Philippe-Jean Bousquet, Public Health Physician and Director of Observation, Data Science and Evaluation – French National Cancer Institute
Discover, in this second video on the Institute, that she expects a frank and constructive commitment from all players in this Association project, in order to set up data reuse projects in oncology to federate the ecosystem and provide access to new data sources.
10 cancer data reuse projects in oncology in 2 years
Since 2021, the Intelligence Artificial and Cancers Association has been working alongside health industry companies, the French National Cancer Institute and the Health Data Hub, transforming healthcare data into therapeutic and diagnostic innovations for cancer patients. To date, ten cancer data reuse projects, led by health industry companies on themes with strong health stakes, have […]
The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Thierry Breton, General Manager of the French National Cancer Institute
In this eighth interview, you’ll find out why the Institute decided to get involved in this project, mobilizing public and private partnership to serve patients.
Optimizing care pathways for better patient care
The care pathway corresponds to comprehensive patient care: it covers the phases of prevention, diagnosis, treatment and follow-up, involving a multitude of healthcare professionals. Influenced by many factors (individual, territorial, etc.), these care paths are highly diverse, with varying degrees of efficiency, and are sometimes subject to delays or disruptions, resulting in lost opportunity for […]
Better monitoring of “early access” patients
The French National Authority for Health defines early access as a system that enables patients who have reached a therapeutic impasse to benefit, on an exceptional and temporary basis, from certain drugs that are not authorized for a specific therapeutic indication. To this end, a certain amount of data (patient characteristics, treatment efficacy, quality of […]
The Artificial Intelligence & Cancer Association and the commitment of its Administrators: Interview with Stéphanie Combes, Director of the Health Data Hub
In this seventh interview, you will discover why the Hub, which provides medical administrative data as well as other data sources from its catalog, has decided to get involved in this Pathway project.
The Artificial Intelligence & Cancers Association and the Commitment of its Administrators: Interview with Golriz Pahlavan, Medical Director – MSD France
For this sixth interview, we present to you Golriz Pahlavan, Medical Director at MSD France, who will answer our three questions. You will discover why this laboratory, which is currently investing in vaccinology and specialty products such as infectious diseases, HIV, immunology, and oncology, has decided to support this Association project.
The Artificial Intelligence & Cancers Association and the commitment of its administrators: Interview with Nuria Perez-Cullell, Medical Director, Patient Consumer – Pierre Fabre Laboratories
For this fifth interview, we are pleased to introduce Nuria Perez-Cullell, Medical Director, Patient Consumer, of Pierre Fabre Laboratories, who will answer our three questions. You will discover why this pharmaceutical group, a strong partner in innovation in France and committed to public health issues, has decided to join the Filière project.
The Artificial Intelligence & Cancers Association and the commitment of its administrators: Interview with Olivier Perche, Head of Public Affairs and Market Access – Roche Diagnostics
For this new interview, we will introduce you to Olivier Perche, Head of Public Affairs and Market Access at Roche Diagnostics, who will answer our three questions. You will discover why this healthcare group, present throughout the patient’s journey and the entire healthcare continuum through its pharmaceutical and diagnostic activities, has decided to engage with […]
The Artificial Intelligence & Cancers Association and the commitment of its administrators: Interview with Nathalie Varoqueaux, Medical Director – AMGEN
For our third interview, it will be Nathalie Varoqueaux, Medical Director at AMGEN, who will answer our questions. You will discover why the global leader in biotechnology has decided to join this industry project.